Total trials
69
Active
10
Phase 3
21
Total enrollment
15,771
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Antifibrotic drugs | — | — | — | — | — | 1 | |
| MMF Immunosuppression | — | — | — | — | — | 1 |
Next readouts
- 2026-07
Top conditions
- Coronary Artery Disease6
- Platelet Reactivity5
- Morbid Obesity5
- Acute Coronary Syndrome4
- Sport Injury3
- Diabetes Mellitus2
- Endothelial Function2
- Risk Factors2
Frequently asked questions about University of Patras
- How many clinical trials does University of Patras have on ClinicalTrials.gov?
- University of Patras is listed as the lead sponsor on 69 clinical trials in ClinicalTrials.gov, 10 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Patras's trials are in Phase 3?
- 21 of University of Patras's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does University of Patras focus on?
- University of Patras's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Platelet Reactivity, Morbid Obesity, Acute Coronary Syndrome, Sport Injury.
- When are University of Patras's next clinical trial readouts?
- University of Patras has 1 upcoming primary-completion readout tracked here; the soonest is “Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD”, expected around 2026-07.